Regulatory issues for Medical Cannabis

An increasing number of countries have taken steps to decriminalize the use and possession of cannabis, and recently the first few territories have fully legalized the drug (Uruguay, some US states).  At the same time, no country has yet formally acknowledged cannabis or cannabis-based products as conventional, registered medication, mainly due to the lack of solid clinical proof on the safety and efficacy of these products in systematic reviews. This has created confusing and sometimes contrasting situations. Below, we outline the regulatory issues that are relevant to the most important stakeholders in the production, prescribing and use of medicinal cannabis products, i.e.: producers, patients, prescribers and researchers.An increasing number of countries have taken steps to decriminalize the use and possession of cannabis, and recently the first few territories have fully legalized the drug (Uruguay, some US states).  At the same time, no country has yet formally acknowledged cannabis or cannabis-based products as conventional, registered medication, mainly due to the lack of solid clinical proof on the safety and efficacy of these products in systematic reviews. This has created confusing and sometimes contrasting situations. Below, we outline the regulatory issues that are relevant to the most important stakeholders in the production, prescribing and use of medicinal cannabis products, i.e.: producers, patients, prescribers and researchers.

Comments